We found that the CXCR4 inhibitor plerixafor reversed the effects of CXCR4 overexpression but most importantly also affected growth and invasiveness of miR‐9 knockdown cells in the HNSCC cell lines (Fig. 6). This evidence concerns the gene CXCR4 and head and neck squamous cell carcinoma.